When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.

Thomas Patrick Kelly net worth and biography

Thomas Kelly Biography and Net Worth

CFO of Deciphera Pharmaceuticals

Tucker Kelly is Executive Vice President, Chief Financial Officer and Treasurer of Deciphera Pharmaceuticals. Mr. Kelly joined Deciphera in 2015 and has more than 20 years of experience in the life sciences industry as a Chief Financial Officer, investment banker, and lawyer. Before joining Deciphera, Mr. Kelly served as Chief Financial Officer of various public and private life sciences companies including AdvanDx, Inc., deCODE genetics, Inc., and Critical Therapeutics, Inc. Prior to becoming a chief financial officer, Mr. Kelly was a life sciences investment banker at Robertson Stephens and Canaccord Adams and earlier in his career was an attorney in the corporate and securities group of Foley, Hoag and Elliot, LLP. Mr. Kelly received a B.S. in Foreign Services cum laude from the Georgetown University School of Foreign Service and a J.D. with honors from the University of Chicago Law School.

What is Thomas Patrick Kelly's net worth?: The estimated net worth of Thomas Patrick Kelly is at least $923,946.20 as of October 30th, 2023. Mr. Kelly owns 63,068 shares of Deciphera Pharmaceuticals stock worth more than $923,946 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Kelly may own. Additionally, Mr. Kelly receives an annual salary of $778,850.00 as CFO at Deciphera Pharmaceuticals. Learn More about Thomas Patrick Kelly's net worth.
How old is Thomas Patrick Kelly?: Mr. Kelly is currently 53 years old. There are 4 older executives and no younger executives at Deciphera Pharmaceuticals. The oldest executive at Deciphera Pharmaceuticals is Dr. Matthew L. Sherman M.D., Executive VP & Chief Medical Officer, who is 68 years old. Learn More on Thomas Patrick Kelly's age.
What is Thomas Patrick Kelly's salary?: As the CFO of Deciphera Pharmaceuticals, Inc., Mr. Kelly earns $778,850.00 per year. There are 2 executives that earn more than Mr. Kelly. The highest earning executive at Deciphera Pharmaceuticals is Mr. Steven L. Hoerter, President, CEO & Director, who commands a salary of $1,240,000.00 per year. Learn More on Thomas Patrick Kelly's salary.
How do I contact Thomas Patrick Kelly?: The corporate mailing address for Mr. Kelly and other Deciphera Pharmaceuticals executives is 200 SMITH STREET, Waltham MA, 02451. Deciphera Pharmaceuticals can also be reached via phone at (781) 209-6400 and via email at [email protected]. Learn More on Thomas Patrick Kelly's contact information.
Has Thomas Patrick Kelly been buying or selling shares of Deciphera Pharmaceuticals?: Thomas Patrick Kelly has not been actively trading shares of Deciphera Pharmaceuticals over the course of the past ninety days. Most recently, Thomas Patrick Kelly sold 2,316 shares of the business's stock in a transaction on Monday, October 30th. The shares were sold at an average price of $12.02, for a transaction totalling $27,838.32. Following the completion of the sale, the chief financial officer now directly owns 63,068 shares of the company's stock, valued at $758,077.36. Learn More on Thomas Patrick Kelly's trading history.
Who are Deciphera Pharmaceuticals' active insiders?: Deciphera Pharmaceuticals' insider roster includes James Bristol (Director), Daniel Flynn (Insider), Thomas Kelly (CFO), Matthew Sherman (EVP), and Michael Taylor (Director). Learn More on Deciphera Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Deciphera Pharmaceuticals?: In the last year, Deciphera Pharmaceuticals insiders bought shares 2 times. They purchased a total of 21,000 shares worth more than $291,260.00. In the last year, insiders at the sold shares 9 times. They sold a total of 37,550 shares worth more than $470,122.61. The most recent insider tranaction occured on January, 16th when EVP Matthew L Sherman sold 2,435 shares worth more than $35,234.45. Insiders at Deciphera Pharmaceuticals own 4.4% of the company. Learn More about insider trades at Deciphera Pharmaceuticals.
Information on this page was last updated on 1/16/2024.

Thomas Patrick Kelly Insider Trading History at Deciphera Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/30/2023	Sell	2,316	$12.02	$27,838.32	63,068
2/16/2023	Sell	1,370	$15.10	$20,687.00	58,795
2/16/2022	Sell	1,368	$9.05	$12,380.40
9/10/2020	Sell	3,000	$47.71	$143,130.00	13,040
9/8/2020	Sell	6,000	$45.49	$272,940.00	13,040
5/11/2020	Sell	12,000	$55.19	$662,280.00	19,040
1/3/2020	Sell	4,359	$57.35	$249,988.65	7,641
10/28/2019	Sell	3,750	$44.34	$166,275.00
9/11/2019	Sell	11,250	$34.97	$393,412.50
8/13/2019	Sell	11,250	$41.27	$464,287.50
6/19/2019	Sell	177	$25.00	$4,425.00
6/3/2019	Sell	2,100	$25.20	$52,920.00
5/22/2019	Sell	1,473	$25.06	$36,913.38
5/1/2019	Sell	13,500	$22.93	$309,555.00
2/19/2019	Sell	1,500	$30.00	$45,000.00
1/7/2019	Sell	5,000	$25.18	$125,900.00

Thomas Patrick Kelly Buying and Selling Activity at Deciphera Pharmaceuticals

Deciphera Pharmaceuticals Company Overview

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $14.65

$14.09

$14.84

50 Day Range

MA: $15.61

$14.18

$17.36

2 Week Range

Now: $14.65

$9.90

$17.73

Volume

329,841 shs

Average Volume

520,713 shs

Market Capitalization

$1.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

The Gold Grab of the Century

From Colonial Metals | Ad

When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.

Thomas Kelly Biography and Net Worth

What is Thomas Patrick Kelly's net worth?

How old is Thomas Patrick Kelly?

What is Thomas Patrick Kelly's salary?

How do I contact Thomas Patrick Kelly?

Has Thomas Patrick Kelly been buying or selling shares of Deciphera Pharmaceuticals?

Who are Deciphera Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Deciphera Pharmaceuticals?